Pharming Group NV ADR (PHAR): Next-Year EPS Estimate 90.57%
As of 2026-05-07, Pharming Group NV ADR (PHAR) has a next-year EPS growth estimate of 90.57%.
On 2026-05-07, analyst consensus for PHAR's next-year EPS growth shifted from 102.61% to 90.57% — a negative change of 12.04 percentage points. Current-year growth is projected at 238.12%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 90.57%
- EPS growth this year
- 238.12%
- EPS next quarter (est)
- $0.05
- Last price
- $12.00
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-07 | 90.57% | 238.12% | $0.05 | $12.00 |
| 2026-05-06 | 102.61% | 211.88% | $0.00 | $16.40 |
| 2026-05-05 | 102.61% | 211.88% | $0.00 | $16.17 |
| 2026-05-04 | 102.61% | 211.88% | $0.00 | $16.39 |
| 2026-05-03 | 102.61% | 211.88% | $0.00 | $16.98 |
| 2026-04-30 | 80.97% | 407.00% | $0.00 | $16.53 |
| 2026-04-29 | 80.97% | 407.00% | $0.00 | $16.35 |
| 2026-04-28 | 80.97% | 407.00% | $0.00 | $16.42 |
| 2026-04-27 | 80.97% | 407.00% | $0.00 | $16.92 |
| 2026-04-26 | 80.97% | 407.00% | $0.00 | $16.68 |
| 2026-04-24 | 80.97% | 407.00% | $0.00 | $16.68 |
| 2026-04-23 | 80.97% | 407.00% | $0.00 | $16.64 |
| 2026-04-22 | 80.97% | 407.00% | $0.00 | $17.08 |
| 2026-04-21 | 80.97% | 407.00% | $0.00 | $17.13 |
| 2026-04-20 | 80.97% | 407.00% | $0.00 | $17.57 |
| 2026-04-19 | 80.97% | 407.00% | $0.00 | $17.34 |
| 2026-04-16 | 80.97% | 407.00% | $0.00 | $17.33 |
| 2026-04-15 | 80.97% | 407.00% | $0.00 | $17.80 |
| 2026-04-14 | 80.97% | 407.00% | $0.00 | $17.68 |
| 2026-04-13 | 80.97% | 407.00% | $0.00 | $16.96 |
| 2026-04-12 | 80.97% | 407.00% | $0.00 | $17.09 |
| 2026-04-10 | 80.97% | 407.00% | $0.00 | $17.12 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Pharming Group NV ADR's next-year EPS growth estimate?▾
As of 2026-05-07, Pharming Group NV ADR (PHAR) has a next-year EPS growth estimate of 90.57%, based on analyst consensus.
When was the latest EPS estimate revision for PHAR?▾
The most recent revision occurred on 2026-05-07, when analysts adjusted the next-year EPS growth estimate from 102.61% to 90.57%.
What sector and industry does Pharming Group NV ADR belong to?▾
Pharming Group NV ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. PHAR appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Pharming Group NV ADR (PHAR) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports